Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 462

Results For "CENT"

4757 News Found

Wipro GE Healthcare introduces remote monitoring solution for COVID 19
Healthcare | August 04, 2021

Wipro GE Healthcare introduces remote monitoring solution for COVID 19

Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution


Abbott receives FDA clearance for its imaging tech using AI
Digitisation | August 04, 2021

Abbott receives FDA clearance for its imaging tech using AI

Ultreon 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using AI -


PLI Scheme to generate export potential of Rs 196,000 crore by 2027 : Mandaviya
Policy | August 03, 2021

PLI Scheme to generate export potential of Rs 196,000 crore by 2027 : Mandaviya

The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales


NPPA monitors and caps prices of essential drugs: Mandaviya
Policy | August 03, 2021

NPPA monitors and caps prices of essential drugs: Mandaviya

NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level


Meddo acquires Doxper in a cash and stock deal
Healthcare | August 03, 2021

Meddo acquires Doxper in a cash and stock deal

This deal makes Meddo, one of the largest health-tech players in India


API exports surpass imports by value in 2020-21
Policy | August 03, 2021

API exports surpass imports by value in 2020-21

The govt has rolled out three schemes for promoting the manufacture of API


AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials


Ajanta Pharma aims to file 10-12 ANDAs per annum
News | August 02, 2021

Ajanta Pharma aims to file 10-12 ANDAs per annum

India business is growing as per projections; whereas US business will bounce back soon.


Granules India earmarks Rs 400 crore as Capex for FY 22
News | August 02, 2021

Granules India earmarks Rs 400 crore as Capex for FY 22

The company has an outlay of Rs 120-140 crore as R & D expense for FY 22


Clinical trials in the UK to study the efficacy of Ashwagandha on COVID 19 patients
Drug Approval | August 02, 2021

Clinical trials in the UK to study the efficacy of Ashwagandha on COVID 19 patients

Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine